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role of LCAT in atherosclerosis remains elusive, the consen-
sus is that a continued study of both the enzyme and disease 
will lead toward better treatments for patients with heart dis-
ease and FLD.—Norum, K. R., A. T. Remaley, H. E. Miet-
tinen, E. H. Strøm, B. E. P. Balbo, C. A. T. L. Sampaio, I. Wiig, 
J. A. Kuivenhoven, L. Calabresi, J. J. Tesmer, M. Zhou, D. S. 
Ng, B. Skeie, S. K. Karathanasis, K. A. Manthei, and K. 
Retterstøl. Lecithin:cholesterol acyltransferase: symposium 
on 50 years of biomedical research from its discovery to lat-
est findings. J. Lipid Res. 2020. 61: 1142–1149.
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IN MEMORIAM: KAARE R. NORUM (1932–2019)
Dr. Kaare R. Norum, our dear colleague and professor at 
the University of Olso, passed away on November 22, 2019 
while in the process of preparing this article (Fig. 1). He 
Abstract LCAT converts free cholesterol to cholesteryl es-
ters in the process of reverse cholesterol transport. Familial 
LCAT deficiency (FLD) is a genetic disease that was first de-
scribed by Kaare R. Norum and Egil Gjone in 1967. This re-
port is a summary from a 2017 symposium where Dr. Norum 
recounted the history of FLD and leading experts on LCAT 
shared their results. The Tesmer laboratory shared struc-
tural findings on LCAT and the close homolog, lysosomal 
phospholipase A2. Results from studies of FLD patients in 
Finland, Brazil, Norway, and Italy were presented, as well as 
the status of a patient registry. Drs. Kuivenhoven and Cal-
abresi presented data from carriers of genetic mutations 
suggesting that FLD does not necessarily accelerate athero-
sclerosis. Dr. Ng shared that LCAT-null mice were protected 
from diet-induced obesity, insulin resistance, and nonalco-
holic fatty liver disease. Dr. Zhou presented multiple innova-
tions for increasing LCAT activity for therapeutic purposes, 
whereas Dr. Remaley showed results from treatment of an 
FLD patient with recombinant human LCAT (rhLCAT). Dr. 
Karathanasis showed that rhLCAT infusion in mice stimu-
lates cholesterol efflux and suggested that it could also en-
hance cholesterol efflux from macrophages.  While the 
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was the first to describe familial LCAT deficiency (FLD), a 
rare disease associated with the absence or defective func-
tion of LCAT and low HDL plasma levels. This report is 
a summary of the proceedings from a symposium Dr. 
Norum organized in Oslo, Norway, on May 19, 2017, and 
it is dedicated to him. Dr. Norum was an astute clinical 
observer and a dedicated scientist committed to the un-
derstanding of fundamental scientific processes under-
pinning clinical observations and their translation back 
to the clinic with the ultimate aim to help patients. Dr. 
Norum worked tirelessly to build an international net-
work of clinical and basic scientists to both advance the 
science and help patients around the world. Dr. Norum 
had a big heart and was fond of a good joke. We will miss 
you, Dr. Norum.
In May 2017, a symposium entitled “LCAT-deficiency: 
from phenotype to genotype and beyond” was held at the 
University of Oslo to mark the fiftieth anniversary of the 
first report on FLD. Leading experts with a broad range of 
experience, from clinical to basic research, shared their lat-
est knowledge of LCAT. This report aims to summarize the 
data presented.
THE DISCOVERIES OF LCAT AND FLD: TWO 
SERENDIPITIES (K. R. Norum)
In 1962, John A. Glomset et al. (1) at the University of 
Washington published experiments suggesting the exis-
tence of a transferase capable of catalyzing the transesteri-
fication of fatty acids between the hydroxyl groups of 
cholesterol and of the glycerol of both neutral and acidic 
lipids. This led to the discovery of the enzyme LCAT (2).
In 1966, Kaare R. Norum was developing a method for 
the evaluation of different types of hyperlipidemias. By 
chance, he found an unusual electrophoretic profile in the 
blood plasma of one patient. There was no HDL or pre-
lipoprotein in the plasma of the patient, but it contained 
high amounts of both triglycerides and cholesterol. Almost 
all the plasma cholesterol was unesterified, whereas about 
80–90% of the total serum cholesterol is esterified in nor-
mal plasma. He also found that there was no LCAT activity 
in the serum. The patient had an opaque cornea and re-
lated that her two sisters had the same symptoms, and they 
were also referred to the University Hospital. Egil Gjone, 
the doctor in charge of the patients, and Norum began a 
collaboration to further study this family. None of these 
patients had LCAT activity in their serum, and a new in-
born error of metabolism, FLD, had been discovered and 
was subsequently published in 1967 (3).
When Glomset learned that Norum and Gjone had de-
scribed a disease caused by the lack of LCAT, he eagerly 
contacted them. This led to long-lasting and very fruitful 
research collaboration between Oslo and Seattle. These in-
vestigators showed that the lipoproteins in the plasma of 
the FLD patients were very different from those of healthy 
patients, and in particular, the patients’ plasma lacked 
HDL. In addition, there were large amounts of membranous 
particles in the plasma from these patients. The membranes 
consisted mainly of free cholesterol and phospholipids or-
ganized into multilamellar vesicles, now referred to as li-
poprotein X (LpX) (4).
Further study of the lipoproteins in the blood of the FLD 
patients led to a better understanding of the normal trans-
port of cholesterol in the body (Fig. 2). LCAT, which binds 
to HDL particles, converts chylomicron surface lipids to 
cholesteryl esters and lysolecithin. In addition, cholesterol 
and lecithin in liver-derived VLDLs, which are secreted by 
the liver, are transferred to HDL where the cholesterol is 
esterified by LCAT. HDL is mainly produced in the liver, 
and it is delivered to the blood plasma as nascent small el-
lipsoid HDL particles, consisting mainly of a protein, called 
apoA-I produced in liver and intestine and small amounts 
of cholesterol. The free cholesterol in nascent HDL parti-
cles is esterified by LCAT in blood, and because of its hy-
drophobic nature, esterified cholesterol moves into the 
core of the HDL particle. HDL can also take up free choles-
terol from cells in a process referred to as cellular choles-
terol efflux. The surplus of esterified cholesterol in HDL is 
subsequently transferred to LDL by the plasma protein 
cholesterol ester transfer protein (CETP), and eventually 
delivered to the liver LDL-receptors. Surplus esterified 
cholesterol in HDL is also transferred to the liver directly 
Fig. 1. Kaare R. Norum. Photo taken in 2016 by K. Retterstøl.
 by guest, on Septem
ber 9, 2020
w
w
w
.jlr.org
D
ow
nloaded from
 
1144 Journal of Lipid Research Volume 61, 2020
via SRBI receptors present in the liver, but this process is 
of less quantitative significance in humans (5). This entire 
process whereby cellular cholesterol is effluxed to HDL, 
esterified by LCAT, transferred to LDL by CETP, and deliv-
ered to the liver by LDL is referred to as reverse cholesterol 
transport, a terminology first introduced by Glomset in 
1968 (6) (Fig. 2). The key role that LCAT plays in reverse 
cholesterol transport is in agreement with the animal data 
detailed below.
In healthy patients, the breakdown of chylomicrons, the 
conversion of VLDL to LDL, and the transformation of na-
scent HDL are rapid processes that are thus difficult to ex-
amine. However, in patients with FLD, these lipoprotein 
conversions are blocked. In experiments involving incuba-
tions of FLD patient plasma with purified LCAT, Norum, 
Gjone, and Glomset were able to observe and study these 
processes delineating important steps in lipoprotein conver-
sion and mature normal lipoprotein biogenesis in plasma.
The main symptoms of FLD patients are renal failure 
and corneal opacities. LpX accumulation in tissue appears 
to be the main cause of kidney injury (4, 7). Similar LpX 
accumulation in the cornea may also contribute to corneal 
opacities and impaired vision in these patients. However, 
LpX does not  seem to be  the main  factor  leading  to  im-
paired vision in other lipoprotein disorders, such as partial 
deficiency of LCAT, referred to as fish-eye disease (FED), 
and apoA-I deficiency. FED patients, like FLD patients, 
have low HDL-cholesterol but milder symptoms of corneal 
opacities. Clearly, more work is needed to clarify whether 
LpX, HDL deficiency, or both contribute to the develop-
ment of corneal opacities and visual impairments in these 
patients. A review containing the signs and symptoms, clini-
cal data, and results of the research with these patients has 
been published as a chapter in The Metabolic Basis of Inher-
ited Disease (8).
There has been, and still is, a great interest in LCAT. Ac-
cording to PubMed as of January 2020, there were more 
than 2,000 published papers on LCAT. The complete or 
partial lack of LCAT is a very rare genetic disease with only 
about 100 patients that are known globally. FLD is a devas-
tating disease with no good available therapies. Studies on 
the molecular pathophysiology of FLD not only provide 
hope for a future treatment for these patients, but also pro-
vide valuable information on cholesterol metabolism, trans-
port, and function. Thus, their study could unveil novel 
insights for new therapeutic targets of disorders in lipopro-
tein metabolism and cardiovascular disease beyond FLD.
STRUCTURE AND FUNCTION OF LCAT  
(J. J .G. Tesmer and K. A. Manthei)
The closest homolog of LCAT in the human genome is 
lysosomal phospholipase A2 (LPLA2), and together they 
constitute a family of phospholipases that transfer the acyl 
chain from lipids, such as lecithin, to acceptor lipids, such 
as ceramide or cholesterol. LPLA2 and LCAT are impor-
tant for lung surfactant catabolism and reverse cholesterol 
transport to the liver via HDL, respectively, and are both 
important targets for biotherapeutic development. The 
Tesmer laboratory has determined atomic resolution crys-
tal structures for both LPLA2 and LCAT (9–11) and is 
working toward understanding the molecular mechanisms 
underlying disease-causing variants as well as small molecu-
lar activators that could be used to treat acute coronary syn-
drome and/or fatal genetic diseases such as FLD. These 
structure-based studies have allowed for the creation of an 
accurate map of the position of disease-causing mutations 
and have revealed unexpected structural features that are 
believed to be involved in membrane and substrate bind-
ing and in catalysis. A notable structural difference be-
tween LPLA2 and LCAT is found in a flexible lid element 
that blocks access to the active site of LCAT. The molecular 
basis for LCAT activation by apoA-I-containing HDLs is 
therefore hypothesized to involve retraction of this lid ele-
ment in a form of interfacial activation (10). Based on mul-
tiple crystal structures and hydrogen deuterium exchange 
data, it is now apparent that this dynamic lid is able to pro-
tect the LCAT active site from solvent (Fig. 3) (10).
The structure of LCAT bound to an LCAT-activating 
compound as well as an acyl intermediate state mimic, iso-
propyl dodecylfluorophosphonate, has also been reported 
(Fig. 3) (11). The combination of these two ligands pro-
motes a lid-open conformation and full access to the active 
site. The Tesmer laboratory has confirmed that the activa-
tor compound binds to an allosteric site via site-directed 
Fig. 2. Reverse cholesterol transport. Cholesterol is 
effluxed from arterial macrophages to pre-HDL, 
where it is esterified by LCAT. The cholesteryl ester 
(CE) then enters the center of the HDL and promotes 
maturation to larger and more spherical particles. 
HDL transports CEs directly to the liver, or via LDL 
when they are transferred by CETP. Cholesterol is then 
excreted in bile and other components are recycled.
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mutants that both eliminate compound binding and de-
crease the thermal stability of LCAT. The activator en-
hances the acyltransferase activity of LCAT R244H in vitro. 
Such studies pave the way for the design of rational drugs 
or improved biotherapeutics that may be used to treat cor-
onary heart disease (CHD) and the renal disease that re-
sults from FLD. The new structure also allows for a better 
understanding of the acyl binding site of LCAT and its cata-
lytic mechanism. Since the symposium, the Tesmer labora-
tory has used electron microscopy to visualize LCAT bound 
to the edge of discoidal HDL particles (12).
PATIENTS WITH FLD
Finland (H. E. Miettinen)
Three families with FLD have been identified in Finland 
(13–15). The common feature of the index patients was 
low serum HDL-cholesterol concentration. Otherwise their 
phenotypes and serum and lipoprotein lipid compositions 
differed greatly.
In family 1, corneal opacities, anemia, and stomatocytes 
(abnormal erythrocytes) in peripheral blood were present. 
One of the subjects had mild proteinuria. Affected family 
members were compound heterozygotes for LCAT R399C 
and exon one C-insertion mutations. In family 2, the pro-
band had anemia and an increased number of stomato-
cytes in his peripheral blood. There were no other clinical 
findings. He was homozygous for the LCAT R399C muta-
tion, which underlines a phenotype with characteristics of 
both FLD and FED. In family 3, the proband had corneal 
opacifications, mild microalbuminuria, and anemia with 
target cells in his peripheral blood. He was homozygous for 
the LCAT G230R mutation, designated as LCAT Fin, which 
represents a complete deficiency (FLD).
Frequencies of these LCAT mutations were examined in 
Finnish subjects with extremely low serum HDL-cholesterol 
concentration (<0.7 mmol/l, n = 156). The LCAT Fin 
mutation was found in 5% of the subjects with low HDL-
cholesterol, and it represents the most common genetic 
cause of reduced HDL-cholesterol levels in southwestern 
Finland (6). There was no evidence suggesting association 
of LCAT mutations with coronary artery disease.
Brazil (B. E. P. Balbo and C. A. T. L. Sampaio)
Based on the identification of three unrelated cases 
of FLD from the same geographical region in Northern 
Brazil, Balbo and Sampaio developed an active search pro-
gram to identify at-risk individuals by clinical and genetic 
screening. This retrospective study included clinical, labo-
ratory, and molecular genetic analyses of 38 FLD patients 
from seven different families. Twenty males and 18 females 
had the diagnosis of FLD established at a mean age of 38.6 
± 16.4 years. Three pathogenic mutations in the LCAT 
gene were identified, each of them corresponding to a 
distinct geographic disease cluster: c.G803A (p.R244H), 
c.C4920T (p.T274I), and c.A2822T (p.I203F).
Phenotypic analysis was performed in all FLD patients. 
HDL-cholesterol was 0.26 mmol/l in all patients, while 
the mean apoA-I and apoB levels were 0.45 ± 0.10 g/l and 
0.41 ± 0.19 g/l, respectively. LDL-cholesterol was >3.75 
mmol/l in two patients and triglycerides <1.7 mmol/l in 15 
patients. Corneal opacities were detected in 36 cases. 
Scheimpflug densitometry was performed in three individ-
uals, revealing high corneal density. Anemia was observed 
in 25 cases (Hb of 10.7 ± 2.2 g/dl) and moderate to severe 
anemia was detected in almost all patients with advanced 
renal insufficiency. Hemolysis, detected by indirect biliru-
bin levels, was observed in 20 individuals. LDH and hap-
toglobin levels, however, were abnormally elevated and 
reduced, respectively, in only two patients. Decreased resis-
tance of red blood cells to osmotic stress was found in all 
five evaluated patients; in their samples, the percentage of 
hemolysis in progressively lower concentrations of sodium 
chloride was below the lower reference range for the stan-
dardized test, indicating osmotic fragility in the red blood 
cells. A high intra- and interfamilial variability in estimated 
glomerular filtration rate was detected and seven patients 
developed end-stage kidney disease at a median age of 38.3 
± 14.2 years. Systemic arterial hypertension was diagnosed 
Fig. 3. Crystal structures reveal a dynamic lid that shields the ac-
tive site of LCAT. Two crystal structures are overlaid to highlight lid 
movement. The closed conformation (Protein Data Bank code 
5TXF) is indicated with a filled arrowhead and red lid, and an open 
state of LCAT (Protein Data Bank code 6MVD) bound to an activa-
tor (purple) is indicated with an open arrowhead and magenta lid. 
Unmodeled residues in the lid are indicated by a dashed line. The 
/-hydrolase domain is colored in orange, the cap domain in 
blue, and the membrane binding domain in teal. The active site 
residue Ser181 is indicated with orange ball-and-sticks, whereas 
Arg244, which is mutated in FLD, is shown in the lid with red and 
magenta ball-and-sticks. N and C indicate the amino and carboxyl 
termini, respectively, observed in the structures.
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in 22 cases, being associated with age >30 years and esti-
mated glomerular filtration rate <83 ml/min/1.73 m2 
(CKD-EPI).
Of the 38 patients, eight patients underwent kidney bi-
opsy, which revealed glomerular deposits in all cases and 
glomerular sclerosis in seven cases. Endocapillary prolifera-
tion and glomerular basement membrane splitting were 
present in four cases, while interstitial fibrosis varied from 
<5% to 60%. The biopsies revealed thrombotic microangi-
opathy in three cases and dominance/codominance of C3 
mesangial deposits in all analyzed samples. In addition to 
the effect of abnormal cholesterol deposition in the kid-
ney, these data suggest that thrombotic microangiopathy 
and C3 deposits may also play a role in the FLD-associated 
renal injury, supporting a pathogenic effect related to the 
activation of the alternative complement pathway.
Norway (E. H. Strøm)
There are four patients identified in Norway. Here, 
we present the case of a 22-year-old male patient with 
edema, hypertension, hematuria, and nephrotic protein-
uria. A renal biopsy revealed changes consistent with LCAT 
deficiency. The patient’s lipid profile was abnormal, with 
especially low HDL-cholesterol 0.3 mmol/l (normal range 
0.8–2.1 mmol/l). He was compound heterozygous for mu-
tations R244H and M252K in exon 6 of the LCAT gene and 
given a diagnosis of FLD. His mother was heterozygous for 
the M252K mutation, while the father was heterozygous for 
the R244H mutation.
At the age of 28, he received a kidney graft from his 
58-year-old father. Two days after transplantation, he had a 
biopsy-proven rejection. Electron microscopy of this biopsy 
showed manifestations of LCAT deficiency. Protocol biop-
sies taken at 6 weeks and 1 year after transplantation dem-
onstrated progression of deposits. Renal function remained 
stable. The renal morphology of this disease is characteris-
tic, and the diagnosis should be suspected from the ultra-
structural findings (16).
A WORLDWIDE REGISTRY ABOUT ALL THE 
KNOWN PATIENTS WITH FLD (I. Wiig)
As of today, less than 100 patients are known. The Nor-
wegian National Advisory Unit on Rare Disorders was asked 
to take initiative to establish a worldwide contact registry 
on FLD. This proved to be difficult. Registries on diseases 
are subject to strict national and international regulations 
like the European General Data Protection Regulation 
(17). As a consequence, contact lists for patients have to be 
organized by patient organizations or through social media 
groups by patients themselves. The Norwegian National 
Advisory Unit on Rare Disorders has developed a national 
quality registry on rare congenital or genetic diseases. En-
tering consenting patients to the registry is done by medi-
cal staff and started in 2019. LCAT deficiency is also 
incorporated in a workgroup for metabolic nephropathies 
in the European Reference Network for Rare Kidney Dis-
eases, ERKNet.
GENETIC FLD AND ATHEROSCLEROSIS  
(J. A. Kuivenhoven and L. Calabresi)
Based on epidemiological findings, the severe deficiency 
of HDL in LCAT-deficient carriers should dramatically in-
crease their risk of developing CHD; however, imaging 
studies evaluating carotid intima-media thickness (IMT), a 
validated surrogate marker for atherosclerotic CHD, have 
not provided such evidence. The first study on LCAT-defi-
cient cases from a large Canadian kindred followed for 
more than 20 years, revealed a slightly increased carotid 
IMT, which did not progress over 4 years (18). In a subse-
quent study of five Dutch FED families, the inheritance of 
LCAT gene mutations only caused a modest increase in ca-
rotid IMT (19). The Dutch heterozygotes also showed ac-
celerated carotid atherosclerosis when assessed by 3.0 T 
magnetic resonance imaging and increased arterial stiff-
ness (20, 21). In contrast, a study of Italian FLD families 
showed that the inheritance of a mutated LCAT genotype 
had a remarkable gene-dose-dependent effect in reducing 
carotid IMT (22), whereas a subgroup of these carriers also 
showed normal flow-mediated dilation (23). Despite the 
obvious difficulties in determining the prevalence of CHD 
in individuals with rare genetic disorders, and the fact that 
carotid IMT remains a surrogate marker of clinical CHD, 
the carotid IMT studies in carriers of LCAT gene mutations 
suggest that FLD does not necessarily accelerate athero-
sclerosis. In other words, a complete absence of LCAT ac-
tivity and related near-complete HDL deficiency appears to 
have no or even a positive impact on atherogenesis (24).
NON-CLASSICAL METABOLIC PHENOTYPES OF 
FLD: LESSONS FROM MURINE MODELS (D. Ng)
Loss-of-function mutations causing FLD in humans are 
inherited in an autosomal codominant fashion. FLD is 
characterized by the near absence of LCAT activity, HDL-
cholesterol, and plasma apoA-I, as well as an elevated 
unesterified/total cholesterol ratio. Corneal opacity and 
anemia are highly prevalent, whereas progressive chronic 
glomerulopathy has been reported in some affected sub-
jects. Studies on genetically engineered LCAT-null mice in 
the Ng laboratory and others have recapitulated the major-
ity of the aforementioned characteristics. Moreover, the 
severity was accentuated when crossed into specific trans-
genic models of dyslipidemia. During the course of study-
ing these model animals, they unexpectedly observed 
protective phenotypes from diet-induced obesity, insulin 
resistance, and nonalcoholic fatty liver disease, attributable 
to loss of LCAT (25). Further analyses uncovered an impor-
tant role of cellular cholesterol in modulating the patho-
genesis of nutritional excess-induced ER stress, insulin 
resistance, steatohepatitis, and ectopic brown adipose tis-
sue biogenesis. Specifically, they learned that hepatic ER 
stress is strongly correlated with cholesterol content in the 
hepatocyte ER but not in other cell compartments (26). 
On the other hand, cholesterol from endogenous synthesis 
and dietary sources both contribute to hepatic inflamma-
some activation (27), in part through cholesterol crystal 
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formation. The findings also uncovered a critical role for 
cellular cholesterol in modulating the spontaneous devel-
opment of classical brown adipose tissue in skeletal muscle 
from myoblasts in utero and satellite cells in adults (28).
LCAT THERAPEUTIC INNOVATIONS (M. Zhou)
Innovations in LCAT therapeutics led to the identifica-
tion of three modalities for increasing LCAT activity: a small 
molecule activator (29), a modified recombinant LCAT 
protein (30), and an agonistic human monoclonal anti-
body (31). Lead molecules from these three distinct mo-
dalities all robustly increase LCAT enzymatic activity and 
modulate HDL metabolism, while each presents unique 
properties to meet different clinical needs. Studies aiming 
at understanding the mechanism of LCAT activation iden-
tified a cysteine residue that plays a crucial role in regulat-
ing LCAT catalytic activity. Incremental hypothesis testing 
in the proof-of-concept studies showed that LCAT activation 
modulates HDL particle composition and size, promotes 
reverse cholesterol transport, and attenuates the progres-
sion of atherosclerosis in preclinical disease models.
TREATMENT OF FLD PATIENTS WITH 
RECOMBINANT LCAT (A. T. Remaley)
Because of the success in using enzyme replacement 
therapy for the treatment of several other rare genetic dis-
orders, there has been a recent effort to also develop re-
combinant human LCAT (rhLCAT) as a therapy. The two 
main potential indications for rhLCAT would be for the 
treatment of FLD and for raising HDL-cholesterol for the 
possible treatment of cardiovascular disease.
Although FLD patients can develop severe anemia and 
corneal opacities, the main cause of morbidity and mortal-
ity is renal disease. In animal models, it has been shown 
that  LpX,  which  only  forms  with  the  near  complete  ab-
sence of LCAT, is nephrotoxic and promotes the develop-
ment of renal disease (4). After intravenous infusion, LpX 
gets trapped in the glomerulus where it damages podocytes 
and causes proteinuria in LCAT-KO but not wild-type mice. 
Furthermore,  in  vitro  incubation  of  LpX  with  rhLCAT 
causes its dissolution and accelerates its catabolism in mice 
(32). In addition, a single intravenous treatment of LCAT-
KO mice with rhLCAT markedly raises HDL-cholesterol and 
normalizes their lipoprotein profile for several days (33).
Besides its possible utility for the treatment of FLD, rhL-
CAT may also be beneficial for cardiovascular disease be-
cause of its role in reverse cholesterol transport. Based on 
this concept, and many promising animal studies showing 
that HDL infusion can rapidly reverse atherosclerotic 
plaques, there have been several clinical trials involving the 
infusion of reconstituted pre-HDL-like particles (rHDLs) 
in patients with acute coronary syndrome (34). However, 
the lipid composition used in manufacturing such rHDL 
therapies appears to significantly affect their functionality 
and ultimate efficacy in the clinic (35). In transgenic rab-
bits that express human LCAT (36) or in rabbits treated 
with rhLCAT, it has been shown that LCAT can protect 
against diet-induced atherosclerosis. It should be also 
noted that, in contrast to rabbits that naturally express 
CETP, overexpression of LCAT in mice, which do not natu-
rally express CETP, promotes atherosclerosis, emphasizing 
the importance of CETP in cholesterol processing follow-
ing the LCAT reaction (37).
Based on the above rationale, rhLCAT produced in 
CHO cells has been developed and tested in two human 
studies (sponsored by AlphaCore Pharma). Plasma LCAT 
concentration rapidly rose after the infusion and was dose-
proportional and had an estimated terminal half-life of 42 
h. The low dose of rhLCAT did not change HDL-choles-
terol levels, but HDL-cholesterol increases were observed 
with the other doses and increased as much as 50% in some 
patients on the highest dose. Pre-HDL sharply dropped 
after the infusion, consistent with conversion to larger 
HDL particles due to cholesterol esterification, which was 
confirmed by electrophoresis and by NMR. The rhLCAT 
treatment also increased the capacity of LDL-depleted se-
rum to promote cholesterol efflux from J744 macrophage 
cells. Most of the plasma lipid changes returned to baseline 
after approximately 3–4 days. The overall conclusion from 
this study was that rhLCAT has an acceptable safety profile 
and the expected effect on HDL parameters and thus sup-
ported its future development.
The other human study on rhLCAT was a single patient 
study of an FLD patient with advanced renal disease and 
nearly undetectable HDL-cholesterol levels (38). The pa-
tient was treated every week to every 2 weeks over an ap-
proximately 7 month period, with a dose ranging between 
3 and 9 mg/kg. Treatment with rhLCAT nearly normalized 
HDL-cholesterol levels and it returned to baseline after 
about 3 days. In contrast, the percent of cholesteryl esters 
in plasma, which also normalized after the treatment, re-
mained elevated for over 1 week. In terms of renal func-
tion, the patient showed some minor improvements within 
the first month of treatment but did not show any further 
improvement thereafter. Before starting treatment, the pa-
tient had severe anemia, but it significantly improved from 
8.2 to 10.1 g/dl after a few months of rhLCAT treatment. It 
is difficult to conclude much from this single patient study, 
but it suggests that unlike renal function, the lipid abnor-
malities and anemia in FLD may quickly respond to rhL-
CAT treatment. After the onset of proteinuria, it typically 
takes several decades for FLD patients to develop end-stage 
renal disease, so the early identification of this disorder 
and early treatment with rhLCAT could hopefully prevent 
this outcome.
ACUTE LCAT INFUSION INCREASES  
MACROPHAGE-SPECIFIC CHOLESTEROL EFFLUX 
IN LCAT-DEFICIENT HUMAN apoA-I TRANSGENIC 
MICE (S. K. Karathanasis)
To determine if a single IV injection of rhLCAT induces 
whole body macrophage-specific cholesterol efflux, LCAT-
KO/human apoA-I transgenic mice (LCAT-KO×hapoA-I 
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Tg) were treated with vehicle or rhLCAT followed 10 min 
later by injection with 3H-cholesterol/BSA nanoparticles. 
Plasma was collected via retro-orbital bleeding at 1, 4, 24, 
and 48 h after injection. At the end of the study, all animals 
were euthanized and organs (liver and spleen) were col-
lected. rhLCAT treatment significantly increased (>3-fold) 
the rate of 3H-cholesterol tracer reappearance in the 
plasma, while it decreased tracer appearance in the liver 
and spleen. Also, rhLCAT treatment significantly increased 
plasma HDL-cholesterol mass that was mostly cholesteryl 
ester, suggesting the formation of large mature HDL par-
ticles. rhLCAT treatment did not affect plasma LDL-cho-
lesterol levels or fecal tracer excretion. The lack of 
endogenous CETP in mice may have limited the effective 
delivery of cholesterol to LDL and its eventual uptake and 
excretion by the liver. These results, for the first time, show 
that recombinant LCAT infusion stimulates cholesterol ef-
flux in vivo and suggest that it could also enhance choles-
terol efflux from macrophages in atherosclerotic plaques. 
Several diseases are associated with reduced LCAT mass 
and/or activity, including genetic LCAT deficiencies, isch-
emic heart disease, chronic kidney disease, and certain 
liver diseases. Our current data suggest that rhLCAT treat-
ment may be of therapeutic value in these diseases.
PERSPECTIVES
Although FLD is a very rare disease, the fact that 38 pa-
tients from seven different families in Brazil were recently 
identified suggests that the disease is underdiagnosed and 
may be more prevalent in isolated geographical regions. 
Regardless, studying its underlying pathophysiology has re-
vealed important insights in lipoprotein metabolism and 
function, particularly regarding LCAT, in the context of a 
variety of diseases beyond FLD. For example, it was recently 
reported that rhLCAT rescues the defective HDL function-
ality to promote endothelial NO production in patients 
with acute coronary syndrome (39). Such findings support 
clinical evaluation of rhLCAT in patients with myocardial 
infarction and other cardiovascular diseases involving en-
dothelial cell dysfunction. Similarly, recently published 
data using an animal model of chemically induced primary 
biliary cirrhosis suggests that rhLCAT treatment may be ef-
fective in reducing plasma LpX levels and reduce the risk 
for xanthoma formation, plasma hyperviscosity, and, per-
haps, neuropathies in patients with primary biliary cirrhosis 
(40). Although more basic work is required to understand 
whether these beneficial effects of LCAT are exclusively 
due to its effects in improving HDL function or additional 
direct enzymatic effects in diseased tissues, rhLCAT ther-
apy appears to be promising and the ongoing clinical stud-
ies may reveal new insights to guide patient selection and 
drug optimization and use.
CONCLUDING REMARKS
Fifty years after the discovery of the first patients with 
FLD, the first international meeting was held in May 2017 
on LCAT. This meeting brought together researchers and 
clinicians interested in the role of LCAT in both healthy 
patients and those with FED and FLD. LCAT catalyzes the 
conversion of free cholesterol to cholesteryl esters on HDL 
particles, generating a cholesterol concentration gradient 
that promotes cholesterol outflow from cell membranes. 
This concentration gradient may enhance cholesterol ef-
flux from cells and thus may prevent the development of 
atherosclerosis. Structural studies of LCAT and, specifi-
cally, recent electron microscopy studies probing the 
LCAT-HDL complex are guiding the understanding of 
LCAT activation by apolipoproteins as well as aiding in the 
development of future therapeutics. rhLCAT produced in 
CHO cells has been developed and tested in two human 
studies with promising improvements in both correcting 
the lipoprotein profile and anemia. Any effect on renal 
function was, however, less convincing and suggests that 
treatment before the onset of renal disease may be critical. 
Patients with FLD offer an important opportunity for the 
understanding of cholesterol metabolism because LCAT is 
essential for the normal metabolism of cholesterol in lipo-
proteins. The role of LCAT in atherosclerosis is not yet 
fully understood, underpinning the importance of study-
ing patients with FLD in more detail. As suggested through-
out this report, increasing knowledge of the role of LCAT 
in human health is also expected to allow for the develop-
ment of a better treatment for FLD.
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